Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1999; 81(04): 661-663
DOI: 10.1055/s-0037-1614545
DOI: 10.1055/s-0037-1614545
Letters to the Editor
The Incidence of Factor V Leiden in a Normal Irish Population and Its Relationship to the Laboratory Diagnosis of APC Resistance
Further Information
Publication History
Received
27 October 1998
Accepted after resubmission
10 December 1998
Publication Date:
09 December 2017 (online)
-
References
- 1 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in the majority of Thrombophilic patients. Blood 1993; 82: 1989-93.
- 2 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 1004-8.
- 3 Bertina RM, Koeleman BPC, Koster T, Rosendal FR, Dirven RJ, de Ronde H, van der Velden PA, Reisma PH. Mutation in blood coagulant factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
- 4 Griffin JH, Heeb MJ, Kojima Y. Fernandez JA Hackeng TM, Greengard JS. Activated protein C resistance molecular mechanisms. Thromb Haemost 1995; 74: 444-8.
- 5 Zöller B, Hillarp A, Berntorp E, Dahlbäck B. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annual Rev Med 1997; 48: 45-58.
- 6 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistence). Blood 1995; 85: 1504-8.
- 7 Rees DC, Cox M, Cleeg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
- 8 Rees D. The population genetics of Factor V Leiden. British Journal of Haematology 1996; 95: 579-86.
- 9 Guigliemina P, Rickards O, Camacho O. Prevalence of FV Leiden in Non-European Populations. Thromb Haemost 1997; 77: 329-31.
- 10 Henkins CMA. Bom VVJ, van der Meer J. Lowered APC sensitivity ratio related to increased factor VIII clotting activity. Thromb Haemost 1995; 74: 1198-9.
- 11 Jorquera J, Montoro J, Fernandez M, Aznar J A, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-3.
- 12 Trossaert M, Conard J, Horellou M Samama, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709.
- 13 Svensson PJ, Zöller B, Dahlbäck B. Evaluation of original and modified APC-resistence tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-5.
- 14 Guash JF, Ruud P, Lensen M, Bertina RM. Molecular characterisation of a type 1 quantitative Factor V deficiency in a thrombosis patient that is ‘Pseudohomozygous’ for activated protein C resistance. Thromb Haemost 1997; 77: 252-7.
- 15 Williamson D, Brown K, Luddington R, Baglin C., Baglin T. Factor V Cambridge. A new mutation (Arg306 -Thr). Blood 1998; Vol 91 Feb. 1140-4.
- 16 Reuner KH, Litfin F, Patscheke H. Discrimination between normal wild-type and carriers of coagulation Factor V Leiden mutated by the activated protein C resistance test in the presence of Factor V deficient plasma. Eur J Clin Chem Clin Biochem 1997; Jan 35 (01) 41-5.
- 17 Svensson PJ, Dahlbäck B. Resistance to activated Protein C as a basis for venous thrombosis. New England Journal of Medicine 1994; 330: 517-21.
- 18 Schroder W, Koessling M, Wulff K, Wehnert M, Herrmann F. World distribution of Factor V Leiden mutation. The Lancet 1996; Vol 347: 58-59.
- 19 Lee DH, Henderson P, Blajchman MA. Prevalence of Factor V. arg 506 -gly. In a blood donor population. Thromb Haemost 73. Vol No 6 196 1995